Pleural Fluid Outperforms Plasma for Detection of Clinically Relevant Mutations in Lung Cancer-Associated Malignant Pleural Effusion.
Testing lung fluid alongside blood dramatically improves detection of treatment-resistant cancer mutations, expanding access to targeted therapies for patients with fluid buildup.
This prospective study of 70 NSCLC patients with pleural effusion demonstrates that pleural fluid cfDNA is significantly superior to plasma for detecting driver and resistance mutations, with complementary rather than redundant information from both compartments. These findings support routine NGS analysis of pleural fluid in NSCLC with effusion to expand access to targeted therapies, particularly in patients with negative cytology.
What the study was
- Study design
- Prospective observational study with paired samples (pleural fluid + plasma cfDNA in NSCLC patients with pleural effusion)
- Population
- 70 NSCLC patients with pleural effusion undergoing diagnostic thoracentesis; 49 with pathologically confirmed MPE
- Sample size
- 70
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Archivos de Bronconeumología
Why it surfaced
Prospective, paired-sample design (n=70) provides level 2 evidence that pleural cfDNA is superior to plasma for mutation detection in NSCLC with MPE. Only 16% of patients received targeted therapy despite frequent detection of actionable mutations — this study directly supports practice change to routinely analyze pleural fluid cfDNA in this large patient population.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.